Clotting Disorders

Clotting Disorders

A collection of features and news articles published in ASH Clinical News related to clotting disorders.

Roche Will Donate Hemophilia A Drug to Developing Countries

Roche will donate its new hemophilia A drug emicizumab-kxwh to the World Hemophilia Federation (WHF) Humanitarian Aid Program. Roche joins other companies – including...

Apixaban AVERTs Cancer-Associated Venous Thromboembolism

In the randomized, placebo-controlled AVERT trial, investigators assessed the safety and efficacy of apixaban thromboprophylaxis in patients with cancer considered to be at intermediate-...

New Drug Approvals in Nonmalignant Hematology

In 2018, the U.S. Food and Drug Administration (FDA) set a record for the number of approvals for new therapies – or new indications...

Apixaban Superior to LMWH in Reducing Recurrence of Cancer-Associated VTE

Results from a trial presented at the 2018 ASH Annual Meeting add more support for the use of direct oral anticoagulants in patients with...

How I Treat in Brief: Managing Post-Thrombotic Syndrome

Anat Rabinovich, MD, of Soroka University Medical Center at the Ben-Gurion University of the Negev in Israel and Susan R. Kahn, MD, MSc, of...
WIB_icon

Do Children With CVC-Related Thromboses Need Anticoagulation Treatment?

Results from a prospective study of children who were hospitalized in a pediatric intensive care unit (PICU) revealed that the incidence of central vein...

No Added Benefit When Hydroxyurea Is Combined With Aspirin in Middle-Aged Patients With Essential...

Cytoreductive treatment with hydroxyurea has been shown to reduce the risk of thrombosis in patients with essential thrombocythemia (ET) and high-risk features, which include...
WIB_icon

Pre-emptive Rituximab Prevents Long-Term Relapses in Immune-Mediated TTP

Patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) who have persistent, severe ADAMTS13 deficiency have a high likelihood of relapse, but pre-emptive treatment with rituximab...
WIB_icon

Risk of Thrombosis in Patients With Cancer and Implanted Ports

Although patients with solid-tumor cancers and implanted ports have a high risk for venous thromboembolism (VTE), guidelines advise against routine thromboprophylaxis, given the wide...

Rivaroxaban Fails to Prevent VTE and VTE-Related Mortality After Hospital Discharge

Patients hospitalized for an acute medical illness are at an increased risk for developing venous thromboembolism (VTE) in the six weeks after discharge, but...
Advertisement

Current Issue

February 2019, Volume 5, Issue 3

This issue features a look at the unique challenges of developing treatments for orphan diseases, more coverage of the 2018 ASH annual meeting, and more.